Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Catherine Novack
JONE
Catherine Novack
JonesTrading
Wall Street Analyst
★☆☆☆☆
#2412
on 13Foresight · ranked by our own returns
27%
Success Rate
+7.8%
Average Return
6 of 22 calls profitable · -5.1% vs benchmark
📈 Across the calls we could measure, roughly 27% of Catherine Novack's ratings turned a profit when each position was held for 1 year — averaging +7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 4 Hold 0 Sell
Catherine's Stock Coverage 23 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
SPRB
Spruce Biosciences
 Jun 08, 2026 BUY Strong Buy
+90.8% avg upside
14 analysts
$135.00
157.92% Upside
 +0.0%
KRRO
Korro Bio
 May 08, 2026 BUY Strong Buy
+108.3% avg upside
19 analysts
$23.00
76.98% Upside
 -8.3%
DTIL
Precision BioSciences
 Apr 16, 2026 BUY Strong Buy
+247.1% avg upside
12 analysts
$30.00
340.61% Upside
 -13.7%
RLYB
Rallybio
 Apr 10, 2026 HOLD Buy
+14.8% avg upside
8 analysts
 — +99.9%
TSE:MDNA
Medicenna Therapeutics Corp
 Apr 10, 2026 HOLD Strong Buy
+1091.5% avg upside
9 analysts
 — ·
WVE
Wave Life Sciences
 Mar 26, 2026 BUY Strong Buy
+260.5% avg upside
28 analysts
$35.00
468.27% Upside
 -0.7%
IBIO
Ibio
 Mar 02, 2026 BUY Strong Buy
+244.7% avg upside
11 analysts
$7.00
314.16% Upside
 -45.4%
PVLA
Palvella Therapeutics
 Feb 24, 2026 BUY Strong Buy
+45.3% avg upside
27 analysts
$209.00
84.72% Upside
 -6.1%
LRMR
Larimar Therapeutics
 Feb 24, 2026 BUY Strong Buy
+409.3% avg upside
21 analysts
$13.00
257.05% Upside
 -7.9%
CRNX
Crinetics Pharmaceuticals
 Jan 05, 2026 BUY Strong Buy
+121.2% avg upside
20 analysts
$97.00
170.32% Upside
 -30.9%
SEPN
Septerna, Inc.
 Dec 23, 2025 BUY Strong Buy
+18.2% avg upside
12 analysts
$43.00
18.95% Upside
 +7.8%
AARD
Aardvark Therapeutics, Inc.
 Sep 30, 2025 BUY Buy
+386.3% avg upside
12 analysts
$33.00
739.64% Upside
 -64.1%
CAPR
Capricor Therapeutics
 Sep 25, 2025 BUY Strong Buy
+68.2% avg upside
12 analysts
$29.00
2.13% Upside
 +341.6%
ALDX
Aldeyra Therapeutics
 Aug 08, 2025 BUY Strong Buy
+713.6% avg upside
21 analysts
$9.00
359.10% Upside
 -68.1%
DYN
Dyne Therapeutics
 Jun 25, 2025 BUY Strong Buy
+92.7% avg upside
29 analysts
$30.00
51.50% Upside
 +90.0%
PRQR
ProQR
 May 17, 2025 BUY Strong Buy
+516.3% avg upside
18 analysts
$11.00
481.93% Upside
 -7.0%
RZLT
Rezolute
 May 15, 2025 BUY Strong Buy
+122.8% avg upside
13 analysts
$12.00
139.08% Upside
 -6.2%
FEMY
Femasys
 May 13, 2025 BUY Strong Buy
+1401.7% avg upside
6 analysts
$6.00
48.48% Upside
 -65.4%
DARE
Daré Bioscience
 Nov 15, 2024 BUY Strong Buy
+516.8% avg upside
14 analysts
$13.00
499.11% Upside
 -42.1%
CALC
CalciMedica
 Nov 15, 2024 BUY Buy
+3672.8% avg upside
9 analysts
$15.00
1885.65% Upside
 -9.9%
EQ
Equillium
 Oct 31, 2024 HOLD Strong Buy
+181.9% avg upside
14 analysts
 — +63.9%
PPBT
Purple Biotech
 Jun 03, 2024 BUY Strong Buy
+2155.0% avg upside
4 analysts
$60.00
3429.41% Upside
 -81.7%
GYRE
Gyre Therapeutics
 Nov 15, 2021 HOLD Strong Buy
+212.0% avg upside
15 analysts
 — +25.3%
🔒 18 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Catherine Novack — Frequently Asked Questions
How accurate are Catherine Novack's stock ratings?
Based on the calls 13Foresight could measure, about 27% of Catherine's ratings were profitable over a one-year hold, with an average return of +7.8% per rating, or -5.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Catherine ranked on 13Foresight?
Catherine Novack is currently ranked #2412 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Catherine cover?
Catherine most recently has ratings on SPRB, KRRO, DTIL, RLYB, TSE:MDNA, WVE, IBIO, PVLA, LRMR, CRNX, SEPN, AARD and 11 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.